Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17988729 | 1.00 | MEN1 (0.34) | MEN1KMT2AMAP3K14ALDH1A1HPGD | |
| SCHEMBL12967711 | 1.00 | MEN1 (0.34) | MEN1KMT2AMAP3K14ALDH1A1HPGD | |
| SCHEMBL18068311 | 1.00 | MEN1 (0.34) | MEN1KMT2AMAP3K14ALDH1A1HPGD | |
| SCHEMBL16664281 | 1.00 | MEN1 (0.34) | MEN1KMT2AMAP3K14ALDH1A1HPGD | |
| SCHEMBL2545200 | 1.00 | MEN1 (0.34) | MEN1KMT2AMAP3K14ALDH1A1HPGD | |
| SCHEMBL9617095 | 1.00 | MEN1 (0.34) | MEN1KMT2AMAP3K14ALDH1A1HPGD | |
| SCHEMBL17329444 | 1.00 | MEN1 (0.34) | MEN1KMT2AMAP3K14ALDH1A1HPGD | |
| SCHEMBL15202859 | 1.00 | MEN1 (0.34) | MEN1KMT2AMAP3K14ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL15546669 | 0.97 | MEN1 (0.33) | MEN1KMT2AMAP3K14ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL15546471 | 0.95 | MEN1 (0.32) | MEN1KMT2AMAP3K14ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024213237-A1 | CURABLE ORGANOSILOXANE-MODIFIED REACTION RESINS | WACKER CHEMIE AG (DE) | 2024-10-17 | — | — | WO | claimed |
| CN-114616229-B | Tricyclic compounds and pharmaceutical uses thereof | 镇斗生物科技股份公司 | 2024-09-03 | — | — | CN | claimed |
| CN-114685349-B | Process for preparing cis-exo-bicyclo [2.2.1] heptane-2, 3-dicarboximide | 四川科瑞德制药股份有限公司 | 2023-10-24 | — | — | CN | claimed |
| CN-114685349-A | Process for the preparation of cis-exo-bicyclo [2.2.1] heptane-2, 3-dicarboximide | 四川科瑞德制药股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-114616229-A | Tricyclic compounds and pharmaceutical uses thereof | 镇斗生物科技股份公司 | 2022-06-10 | — | — | CN | claimed |
| WO-2014037886-A1 | PROCESS FOR THE PREPARATION OF LURASIDONE HYDROCHLORIDE | RANBAXY LABORATORIES LIMITED (IN) | 2014-03-13 | — | — | WO | claimed |
| EP-2694499-A1 | PROCESS FOR THE PREPARATION OF AN ANTIPSYCHOTIC AGENT | Ranbaxy Laboratories Limited (IN) | 2014-02-12 | — | — | EP | claimed |
| US-20130303497-A1 | DEUTERATED 5-HT1A RECEPTOR AGONISTS | CONRIG PHARMA APS (DK) | 2013-11-14 | — | — | US | claimed |
| WO-2013121440-A1 | PROCESS FOR PREPARING BENZISOTHIAZOL-3-YL-PEPERAZIN-L-YL-METHYL-CYCLO HEXYL-METHANISOINDOL-1,3-DIONE AND ITS INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2013-08-22 | — | — | WO | claimed |
| WO-2012131606-A1 | PROCESS FOR THE PREPARATION OF AN ANTIPSYCHOTIC AGENT | RANBAXY LABORATORIES LIMITED (IN) | 2012-10-04 | — | — | WO | claimed |
| CN-119033737-A | Oral films comprising lurasidone | LTS罗曼治疗系统股份公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2024213237-A1 | CURABLE ORGANOSILOXANE-MODIFIED REACTION RESINS | WACKER CHEMIE AG (DE) | 2024-10-17 | — | — | WO | disclosed |
| CN-114616229-B | Tricyclic compounds and pharmaceutical uses thereof | 镇斗生物科技股份公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-115611866-B | Preparation method of tandospirone citrate | 南京海纳医药科技股份有限公司 | 2024-04-23 | — | — | CN | disclosed |
| EP-4288442-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | Faxian Therapeutics, LLC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-5158956-A | Administering serotonin receptor agonist | ELI LILLY AND COMPANY (US) | 1992-10-27 | — | — | US | disclosed |
| US-5096908-A | 5-HT1A agonist | ELI LILLY AND COMPANY (US) | 1992-03-17 | — | — | US | disclosed |
| EP-0464846-A1 | Imide derivatives, and their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-01-08 | — | — | EP | disclosed |
| EP-0455510-A2 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | ELI LILLY AND COMPANY (US) | 1991-11-06 | — | — | EP | disclosed |
| US-3941746-A | Containing hindered phenolic norbornane-2,3-dicarboximides stabilized compositions | CIBA-GEIGY CORPORATION (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303497-A1 | DEUTERATED 5-HT1A RECEPTOR AGONISTS | HTR1A, HTR1D, HTR5A | MEN1 1973/4885KMT2A 3290/4885MAP3K14 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.